Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

General Updates | Venetoclax-based salvage therapy in patients with R/R AML previously treated with targeted agents

Jan Bewersdorf • 6 Oct 2023
General Updates
Acute Myeloid Leukemia Leukemia Gilteritinib Ivosidenib Venetoclax

Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses findings from a retrospective analysis investigating the efficacy of venetoclax-based salvage therapy in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) previously treated with FLT3 or IDH inhibitors. This interview was recorded virtually.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jan Bewersdorf

2:00
Optimizing HMA treatment in HR-MDS: azacitidine versus decitabine
Jan Bewersdorf • 10 Dec 2023
2:48
Validation of IWG 2023 criteria for response to treatment with HMA in HR-MDS
Jan Bewersdorf • 10 Dec 2023
1:43
E7820 in combination with venetoclax in patients with splicing factor mutant myeloid malignancies
Jan Bewersdorf • 10 Dec 2023
2:36
Intensive induction chemotherapy vs HMA/Ven in NPM1-mutant AML: a retrospective study
Jan Bewersdorf • 10 Dec 2023

Related Videos

1:17
The curative potential of alloSCT in the treatment of HR-MDS
Jurjen Versluis • 22 Apr 2024
10:34
Remission induction therapy prior to alloSCT in AML: insights from the ASAP trial
Johannes Schetelig • 19 Apr 2024
1:57
The FORUM trials: results of F1 and plans for F2
Christina Peters • 15 Apr 2024
5:28
Young matched unrelated donors versus older-aged matched sibling donors in alloSCT with PTCy
Karthik Nath • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals